AlAseeri et al 2026 — Metformin in MS: AMPK + GDF15 mechanism review
One-paragraph summary
Narrative review of metformin's neuroprotective mechanisms in multiple sclerosis with explicit emphasis on the AMP-activated protein kinase (AMPK) pathway and growth differentiation factor 15 (GDF15) induction as the load-bearing mechanism candidates. The review consolidates preclinical and clinical findings indicating metformin exerts neuroprotective effects by modulating mitochondrial homeostasis, reducing oxidative stress, and attenuating pro-inflammatory pathways. Metformin influences immune-inflammatory responses, improves metabolic balance in neural and immune cells, and potentially ameliorates pathological processes associated with MS disease progression in both human MS and animal models. The authors note the precise mechanisms by which metformin influences MS pathophysiology remain partially elucidated and call for further targeted studies. For the project, this paper consolidates the mechanistic rationale that v0.3 §12.9 leans on — AMPK pathway activation as the framework explanation for metformin's pleiotropic effects in CNS disease. Less primary-data-rich than the Kazakou Nat Commun paper but useful for citation reinforcement and for the GDF15 mechanism specifically (which the project's framework has not yet captured).
Claims as triples
metformin — modulates → mitochondrial_dysfunction[evidence: AMPK-pathway activation review; confidence: emerging (reinforces existing edge)]metformin — modulates → multiple_sclerosis[evidence: review of preclinical + clinical MS studies; confidence: emerging]metformin — modulates → neuroinflammation_glial[evidence: anti-inflammatory pathway modulation review; confidence: emerging]
Methods note
Narrative review. Synthesizes recent preclinical and clinical studies examining cellular and molecular effects of metformin relevant to neurodegeneration and MS. Literature on mitochondrial function, inflammatory signaling, oxidative stress, and metabolic pathways modulated by metformin analyzed to elucidate potential mechanisms in MS. No new primary data.
Limitations
- Review-level evidence; no new primary data.
- GDF15 induction mechanism is novel framing for the project's ontology — GDF15 is not yet an entity in
ontology.yaml. Whether to add it depends on whether subsequent papers connect GDF15 to FM specifically. - AMPK-pathway framing is well-established but the review does not adjudicate among competing mechanisms (AMPK vs. mitochondrial-respiratory-chain inhibition vs. complex I direct effect) for metformin's CNS effects.
- Single review group; recent. The Al-Kuraishy / Batiha lab has produced multiple metformin-mechanism review papers in adjacent neurological-disorder contexts; treat as consolidating a research-program perspective rather than independent assessment.
Open questions raised
- Does GDF15 induction operate in FM patients receiving metformin? GDF15 is a peripheral biomarker that could be added to the biomarker-mapping cohort if it tracks metformin response.
- Is AMPK activation the dominant mechanism for metformin's neuroprotective effects, or is it a downstream consequence of mitochondrial-respiratory-chain modulation? Pharmacological dissection (AMPK activator without metformin's other effects, e.g., AICAR or A769662) would resolve.
Triangulation notes
- Reinforces v0.3 §12.9 metformin arm citation base — adds a peer-reviewed neurology-journal review consolidating the mechanism.
- Compatible with Kazakou 2025 Nat Commun — both papers identify mitochondrial / AMPK pathway as central to metformin's neural effects. Kazakou provides primary data; AlAseeri provides synthesis framing.
- Compatible with Qin 2026 J Integr Neurosci — both papers are EAE-relevant; AlAseeri's AMPK-framing complements Qin's AKT/mTOR/STAT3-framing as parallel intracellular pathways.
Bridges
- B17 reinforced — metformin / AMPK-activator class ↔ FM via mechanistic review consolidating MS-relevant neuroprotective effects.